Primidone Tablets, USP

PRIMIDONE - primidone tablet 
Global Pharmaceuticals

----------

Primidone Tablets, USP

50 mg and 250 mg

Anticonvulsant

Rx only

DESCRIPTION

The chemical name is 5-ethyldihydro-5-phenyl-4,6 (1H,5H)-pyrimidinedione. The molecular weight is 218.25. The molecular formula is C12H14N2O2. Primidone is a white crystalline, highly stable substance, M.P. 279-284° C. It is poorly soluble in water (60 mg per 100 mL at 37° C) and in most organic solvents. It possesses no acidic properties, in contrast to its barbiturate analog. The structural formula is:

Chemical Structure

Primidone 50 mg and 250 mg tablets contain the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, povidone, sodium lauryl sulfate, sodium starch glycolate, talc, and magnesium stearate. Also the 250 mg strength contains FD&C Yellow No. 5 (tartrazine).

CLINICAL PHARMACOLOGY

Primidone tablets raise electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone's antiepileptic action is not known.

Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals.

INDICATIONS AND USAGE

Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.

CONTRAINDICATIONS

Primidone is contraindicated in:

1)
patients with porphyria and
2)
patients who are hypersensitive to phenobarbital (see CLINICAL PHARMACOLOGY).

WARNINGS

The abrupt withdrawal of antiepileptic medication may precipitate status epilepticus.

The therapeutic efficacy of a dosage regimen takes several weeks before it can be assessed.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including primidone tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 1 shows absolute and relative risk by indication for all evaluated AEDs.

Table 1 Risk by indication for antiepileptic drugs in the pooled analysis
IndicationPlacebo Patients with Events Per 1000 PatientsDrug Patients with Events Per 1000 PatientsRelative Risk: Incidence of Events in Drug Patients/ Incidence in Placebo PatientsRisk Difference: Additional Drug Patients with Events Per 1000 Patients
Epilepsy 1.0 3.4 3.5 2.4
Psychiatric5.78.51.52.9
Other1.01.81.90.9
Total2.44.31.81.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing primidone tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Usage in Pregnancy

To provide information regarding the effects of in utero exposure to primidone tablets, physicians are advised to recommend that pregnant patients taking primidone tablets enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.

The effects of primidone tablets in human pregnancy and nursing infants are unknown.

Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause-and-effect relationship.

There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans: the possibility also exists that other factors leading to birth defects, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorders are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.

The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential.

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. Pregnant women under anticonvulsant therapy should receive prophylactic vitamin K1 therapy for one month prior to, and during, delivery.

PRECAUTIONS

The total daily dosage should not exceed 2 g. Since primidone tablet therapy generally extends over prolonged periods, a complete blood count and a sequential multiple analysis-12 (SMA-12) test should be made every six months.

This product contains FD&C Yellow No.5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No.5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

In Nursing Mothers

There is evidence that in mothers treated with primidone, the drug appears in the milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of primidone tablet-treated mothers be taken as an indication that nursing should be discontinued.

Information for Patients

Suicidal Thinking and Behavior

Patients, their caregivers, and families should be counseled that AEDs, including primidone tablets, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Patient should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see Usage in Pregnancy section).

ADVERSE REACTIONS

The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness, and morbilliform skin eruptions. Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistent or severe side effects may necessitate withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to primidone tablets and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication.

DOSAGE AND ADMINISTRATION

Adult Dosage

Patients 8 years of age and older who have received no previous treatment may be started on primidone tablets according to the following regimen using either 50 mg or scored 250 mg primidone tablets:

Days 1 to 3: 100 to 125 mg at bedtime

Days 4 to 6: 100 to 125 mg b.i.d.

Days 7 to 9: 100 to 125 mg t.i.d.

Day 10 to maintenance; 250 mg t.i.d.

For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg primidone tablets daily in divided doses (250 mg t.i.d. or q.i.d.). If required, an increase to five or six 250 mg tablets daily may be made but daily doses should not exceed 500 mg q.i.d.

Figure

Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations of primidone may be necessary for optimal dosage adjustment. The clinically effective serum level for primidone is between 5 to 12 mcg/mL.

In Patients Already Receiving Other Anticonvulsants

Primidone tablets should be started at 100 to 125 mg at bedtime and gradually increased to maintenance level as the other drug is gradually decreased. This regimen should be continued until satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with primidone tablets alone is the objective, the transition from concomitant therapy should not be completed in less than two weeks.

Pediatric Dosage

For children under 8 years of age, the following regimen may be used:

Days 1 to 3: 50 mg at bedtime.

Days 4 to 6: 50 mg b.i.d.

Days 7 to 9: 100 mg b.i.d.

Day 10 to maintenance: 125 mg t.i.d. to 250 mg t.i.d.

For children under 8 years of age, the usual maintenance dosage is 125 to 250 mg three times daily or, 10 to 25 mg/kg/day in divided doses.

HOW SUPPLIED

Primidone tablets, 50 mg, are white to off-white, square, flat-faced bevel-edged tablets, debossed with "C41" on top of bisect on one side and plain on the other.

Bottles of 100............................................................................... NDC 0115-1030-01

Bottles of 500............................................................................... NDC 0115-1030-02

Primidone tablets, 250 mg, are light yellow, square, flat-faced bevel-edged tablets, debossed with "C42" on top of bisect on one side and plain on the other.

Bottles of 100............................................................................... NDC 0115-1031-01

Bottles of 1000............................................................................. NDC 0115-1031-03

Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].

Dispense in tightly-closed, light-resistant container as defined in the USP, with child-resistant closure, as required.

Manufactured by:
IMPAX Laboratories, Inc.
Hayward, CA 94544

Distributed by:
Global Pharmaceuticals
Division of IMPAX Laboratories, Inc.
Philadelphia, PA 19124 USA

Rev. 08/2010
563-04

MEDICATION GUIDE

Primidone Tablets USP, 50 mg and 250 mg

Read this Medication Guide before you start taking primidone tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about primidone tablets?

Do not stop taking primidone tablets without first talking to your healthcare provider.

Stopping primidone tablets suddenly can cause serious problems.

Primidone tablets can cause serious side effects, including:

1.
Like other antiepileptic drugs, primidone tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:
  • thoughts about suicide or dying
  • attempts to commit suicide
  • new or worse depression
  • new or worse anxiety
  • feeling agitated or restless
  • panic attacks
  • trouble sleeping (insomnia)
  • new or worse irritability
  • acting aggressive, being angry, or violent
  • acting on dangerous impulses
  • an extreme increase in activity and talking (mania)
  • other unusual changes in behavior or mood

How can I watch for early symptoms of suicidal thoughts and actions?

Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

Do not stop primidone tablets without first talking to a healthcare provider.

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

What are primidone tablets?

Primidone tablets are a prescription medicine used alone or with other medicines to treat people with:

Who should not take primidone tablets?

Do not take primidone tablets if you:

What should I tell my healthcare provider before taking primidone tablets?

Before you take primidone tablets, tell your healthcare provider if you:

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking primidone tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.

Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.

How should I take primidone tablets?

Take primidone tablets exactly as prescribed. Your healthcare provider will tell you how much primidone tablets to take and when to take it.

What should I avoid while taking primidone tablets?

What are the possible side effects of primidone tablets?

See "What is the most important information I should know about primidone tablets?".

Primidone tablets may cause other serious side effects including:

The most common side effects of primidone tablets include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store primidone tablets?

Store primidone tablets at room temperature between 68ºF to 77ºF (20ºC to 25ºC) in a tight, light-resistant container

Keep primidone tablets and all medicines out of the reach of children.

General Information about primidone tablets

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use primidone tablets for a condition for which it was not prescribed. Do not give primidone tablets to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about primidone tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about primidone tablets that is written for health professionals.

For more information, call 1-800-934-6729.

What are the ingredients in primidone tablets?

Active Ingredient: primidone

Inactive ingredients: microcrystalline cellulose, lactose monohydrate, povidone, sodium lauryl sulfate, sodium starch glycolate, talc, and magnesium stearate. Also the 250 mg strength contains FD&C Yellow No. 5 (tartrazine).

Issued August 2010

This Medication Guide has been approved by the U.S. Food and Drug Administration

Mfg. by:
Impax Laboratories, Inc.
Hayward, CA 94544 USA

Dist. by:
Global Pharmaceuticals
Division of Impax Laboratories, Inc.
Philadelphia, PA 19124 USA

Rev. 08/2010
563-04

PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label

GLOBAL®

NDC 0115-1030-01

Primidone
Tablets, USP

50 mg

PHARMACIST: Dispense the accompanying
Medication Guide to each patient.

Rx only
100 Tablets

PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 250 mg Tablet Bottle Label

GLOBAL®

NDC 0115-1031-01

Primidone
Tablets, USP

250 mg

PHARMACIST: Dispense the accompanying
Medication Guide to each patient.

Rx only
100 Tablets

PRINCIPAL DISPLAY PANEL - 250 mg Tablet Bottle Label

PRIMIDONE 
primidone   tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0115-1030
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PRIMIDONE (PRIMIDONE) PRIMIDONE50 mg
Inactive Ingredients
Ingredient NameStrength
CELLULOSE, MICROCRYSTALLINE 
LACTOSE MONOHYDRATE 
POVIDONE 
SODIUM LAURYL SULFATE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
TALC 
MAGNESIUM STEARATE 
Product Characteristics
ColorWHITE (white to off-white) Score2 pieces
ShapeSQUARE (flat-faced bevel-edged) Size6mm
FlavorImprint Code C41
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
10115-1030-01100 TABLET In 1 BOTTLENone
20115-1030-02500 TABLET In 1 BOTTLENone

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04071702/12/2008

PRIMIDONE 
primidone   tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0115-1031
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PRIMIDONE (PRIMIDONE) PRIMIDONE250 mg
Inactive Ingredients
Ingredient NameStrength
CELLULOSE, MICROCRYSTALLINE 
LACTOSE MONOHYDRATE 
POVIDONE 
SODIUM LAURYL SULFATE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
TALC 
MAGNESIUM STEARATE 
FD&C YELLOW NO. 5 
Product Characteristics
ColorYELLOW (light yellow) Score2 pieces
ShapeSQUARE (flat-faced bevel-edged) Size11mm
FlavorImprint Code C42
Contains    
Packaging
#NDCPackage DescriptionMultilevel Packaging
10115-1031-01100 TABLET In 1 BOTTLENone
20115-1031-031000 TABLET In 1 BOTTLENone

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04071702/12/2008

Labeler - Global Pharmaceuticals (116732830)
Establishment
NameAddressID/FEIOperations
Global Pharmaceuticals116732830REPACK
Revised: 09/2010Global Pharmaceuticals